CohBar (NASDAQ: CWBR) is a clinical-stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases with limited to no treatment options. In November 2022, CohBar announced that it had initiated a process to explore and review a range of strategic alternatives.
Company Profile
Contact Information
Investor Relations
T: (650) 446-7888
Company Contact
CohBar, Inc.
1455 Adams Drive
Suite 1308
Menlo Park, CA 94025
T: (650) 446-7888
info@cohbar.com